Summary. Patients with cancer-associated thrombosis (CAT) carry a higher risk of recurrence, bleeding and mortality as compared with non-cancer patients. The specific profiles of cancer patients, combining frequent co-morbidities, the use of anti-tumoral therapies and the cancer progression itself, represent a major therapeutic challenge for choosing a long-term anticoagulant treatment. This review discusses the practical basis of making a choice between the available drugs for a long-term antithrombotic strategy, linked to their pharmacology, mechanism of action, evidence of clinical benefits, and advantages and limitations in such a complex clinical context. In patients with cancer, low-molecular-weight heparins (LMWHs) are the preferred option for the secondary prevention of venous thromboembolism according to current guidelines, because their efficacy is significantly superior to vitamin K antagonists (VKAs). Even though LMWHs are effective and safe in cancer patients, they require daily subcutaneous injections, which may be problematic for a long-term therapy that may exceed 6 months' duration. Compared with VKAs, non-vitamin-K antagonist oral anticoagulants or direct oral anticoagulants (DOACs) are more target specific and do not require laboratory monitoring, whereas the oral route of administration makes them potentially attractive alternatives to LMWH. In randomized controlled trials in the general population DOACs have been shown to be non-inferior to VKAs in terms of efficacy with a lower rate of clinically relevant or major bleeding.
Introduction
Venous thromboembolic disease is a major clinical challenge in cancer patients, it delays anti-tumoral therapy and is associated with increased risks of bleeding and/or thrombotic recurrence as compared with non-cancer patients [1] . Low-molecular-weight heparins (LMWHs) are the mainstay for the long-term treatment of venous thromboembolism (VTE) in cancer patients. This preference is consistently reflected in all practice guidelines, including those released by the European Society of Medical Oncology [2] , the American College of Chest Physicians [3] , the National Comprehensive Cancer Network [4] , the American Society of Clinical Oncology [5] and the International Society of Thrombosis and Haemostasis [6] . Based on treatment duration, this includes acute treatment (up to 10 days), long-term treatment (3-6 months) and extended treatment in selected patients (beyond 6 months) [3, 7] .
LMWHs are preferred for long-term treatment in cancer patients because they have been shown to be superior to vitamin K antagonists (VKAs) in the prevention of recurrence of VTE [8] [9] [10] . Although it is equally safe, the LMWH effect is more rapidly reversible and therefore it is more flexible in the case of invasive procedures, after which anticoagulation can be rapidly reintroduced. Also, LMWHs have limited drug interactions and their absorption is not influenced by food or gastrointestinal disorders. Conversely, cancer patients receiving VKAs are exposed to the risk of interactions with chemotherapy and food and have variable oral absorption as a result of gastrointestinal disorders [3] ; VKAs have a narrow therapeutic index and frequent laboratory monitoring is required because of the high variability of the anticoagulant effect.
Neverthelesss, LMWHs require daily subcutaneous injections, which may be inconvenient for some patients, especially in those requiring long-term treatment, sometimes beyond 6 months. Also, their use is limited or contraindicated in patients with severe renal dysfunction. Despite the demonstrated superiority of LMWH over VKA treatment in cancer-associated thrombosis (CAT), a large proportion of patients still receive warfarin as longterm treatment [11, 12] . The recently introduced targetspecific direct oral anticoagulants (DOACs) (dabigatran, rivaroxaban, apixaban and edoxaban) are orally active, administered at fixed doses and do not require laboratory monitoring (Table 1) .
This review discusses the basis for an optimal choice of long-term anticoagulant treatment in patients with CAT based on its mechanism of action, clinical efficacy and safety profile.
Patients with cancer-associated VTE: a specific profile
Managing long-term anticoagulant treatment of VTE in cancer patients is complex as the use of concomitant anticancer therapies (chemotherapy, hormones and immunomodulatory or anti-angiogenic drugs), central venous catheter (CVC) placement and invasive cancer surgery further increase the thrombotic risk and expose patients to potential drug interactions. The risk of thrombotic recurrences is usually higher in patients with advanced-stage cancer receiving chemotherapies and subcutaneous growth factors [13] .
Patients with active cancer, especially if it is recently diagnosed, are at much higher risk of VTE recurrence and bleeding compared with patients with only a history of cancer [14] . In this latter category, the incidence of VTE recurrence and bleeding is similar to that reported in patients without cancer [15] .
Renal insufficiency, which is more frequent in cancer patients because of several factors such as chemotherapy toxicity, dehydration or older age, is an independent risk factor for bleeding and represents a critical therapeutic challenge for the choice of an anticoagulant, as up to 50% of patients with cancer may have renal dysfunction [16] . The risk of major bleeding is significantly increased in patients with creatinine clearance below 30 mL min À1 and metastatic cancer [17] , as is the risk of fatal bleeding [18] , because anticoagulants may accumulate as a result of compromised renal elimination. In patients with cancer, the risk of major bleeding is correlated with the degree of renal impairment [19] .
Cancer patients frequently suffer from infections, leading to antibiotic or antimycotic treatments, which cause additional gastrointestinal side-effects such as vomiting, gastric atrophia or diarrhea. All these features must be taken into account because they have a direct implication for pharmacokinetic/pharmacodynamic (PK/PD) properties of oral anticoagulants [14] . Several metabolic pathways involving cytochrome P 450 3A4 (CYP 3A4) and P-glycoprotein (P-gp) must be taken into account in cancer patients. The metabolism of several cancer treatments is influenced by these pathways, and with anticoagulants being metabolized by the same pathways, the pharmacodynamics and pharmacokinetics can be modified through drug-drug interactions (Table 3) .
Elderly patients (aged > 75 years) with cancer are at a particularly high risk of bleeding, not only because of their age and renal dysfunction, but also because of the more frequent side-effects from cancer therapy and their frail situation [20] .
The bleeding risk is also increased because of chemotherapy-induced thrombocytopenia and hepatic or brain metastases. A previous episode of major bleeding in the last 2 months or the presence of an intracranial or visceral tumor increases the risk of major bleeding [21] , as does platelet count falling below 50 000 per lL secondary to chemotherapy [22] .
Long-term use of LMWH in CAT
Meta-analyses of several individual studies on enoxaparin [23, 24] , dalteparin [25] and tinzaparin [26, 27] have shown the superiority of LMWH over VKAs in reducing the risk of VTE recurrence in patients with CAT after up to 6 months' treatment. Relative risk reduction (RRR) with LMWH compared with VKAs ranged from 30% to 59%, with an overall risk reduction of 51% (95% CI, 0.34-0.70), without increased risk of bleeding (RR, 1.05; 95% CI, 0.53-2.10) [8, 9] . More recently, in the 6-month CATCH study, the LMWH tinzaparin, compared with a VKA, was shown to reduce, albeit non-significantly, VTE recurrence (hazard ratio [HR], 0.65; 95% CI, 0.41-1.03), with a significant decrease in occurrence of symptomatic DVT (HR, 0.48; 95% CI, 0.24-0.96) without increase in major bleeding (HR, 0.89; 95% CI, 0.40-1.99) or clinically relevant non-major bleeding (HR, 0.69; 95% CI, 0.49-0.96) [28] . In a more recent meta-analysis of randomized control studies, including the CATCH study, LMWH emerged as significantly superior to VKAs with respect to risk reduction of recurrent VTE (RR, 0.60; 95% CI, 0.45-0.79; P < 0.001), and its safety was comparable to VKAs (RR, 1.08; 95% CI, 0.70-1.66; P = 0.74) [10] .
The usefulness of a duration of LMWH treatment beyond 6 months remains controversial. The use of the LMWH dalteparin up to 12 months (n = 109) was assessed in the prospective observational DALTECAN study. The VTE recurrence rate in months 7-12 was low (4.1%) and similar to that in months 2-6 (3.4%); however, it was two times lower than during the first 6 months (8.7%). Major bleeding was less frequent during dalteparin therapy beyond 6 months [29] . In the Cancer-DACUS study, the discontinuation of LMWH in patients with residual vein thrombosis and active cancer either after 6 or 12 months of LMWH treatment was associated with a high risk of recurrent VTE during the 6 months following the end of anticoagulant treatment, suggesting that these patients should receive anticoagulant therapy over the long term [30] . Data from a cohort study with 358 CAT patients suggest that treatment of cancerassociated VTE with anticoagulants should be stopped in patients with cured cancer, whereas cancer relapse seems to be a strong risk factor for recurrent symptomatic thrombosis [31] .
Clinical efficacy of DOACs in patients with active cancer
In a phase II dose-ranging pilot study, the direct factor (F) Xa inhibitor apixaban used for the prophylaxis of VTE was well tolerated in patients receiving chemotherapy. The rate of major bleeding in the 93 apixaban patients was 2.2% (95% CI, 0.26-7.5%), all of them in the group receiving the dose of 20 mg daily, compared with one major bleeding in the placebo group (n = 30) [32] . With regard to the treatment of VTE in the overall population, DOACs have been shown to be non-inferior to VKAs in the prevention of VTE recurrence and have been associated with a significant reduction in major and fatal bleedings in phase 3 randomized clinical trials [33] ( Table 1 ). There has been no specific phase III study on the use of DOACs in patients with cancer published to date, although several studies in this patient population are ongoing. Clinical efficacy and safety data for DOACs, extracted from subgroups (2-9%) of patients with active cancer, are available for the direct thrombin inhibitor dabigatran etexilate, and the direct inhibitors of FXa, rivaroxaban, apixaban and edoxaban [34] .
A meta-analysis of these subgroups included in six phase III studies (two with dabigatran, two with rivaroxaban, one with edoxaban, and one with apixaban), comparing DOACs with LMWH, overlapped and followed by a VKA, pooled the results of 1132 patients with active cancer [35] . VTE recurred in 23 of 595 and in 32 of 537 cancer patients treated with DOACs and conventional treatment, respectively (odds ratio [OR], 0.63; 95% CI, 0.37-1.10). Major bleeding was reported in 19 patients among the 587 cancer patients receiving DOACs and in 22 patients among the 527 patients in the control group (OR, 0.77; 95% CI, 0.41-1.44). The authors conclude that the efficacy and safety profiles of DOACs are similar to those observed in non-cancer patients and to a non-significant but favorable trend toward reduction of recurrent venous thromboembolism (40% risk reduction) without concerns in terms of major bleeding (30% risk reduction). Another meta-analysis pooling the data from 1581 patients with CAT showed a significantly lower incidence of the first recurrence of VTE with DOACs (3.4%) compared with VKAs (5.9%) (RR, 0.57; 95% CI, 0.36-0.91; P = 0.02), whereas no difference was observed in the risk of major bleeding (RR, 0.77; 95% CI, 0.44-1.33), which suggests a better efficacy of DOACs over VKAs without increasing the risk of major bleeding [36] .
LMWH vs. DOACs for the treatment of CAT
No direct comparison of LMWH vs. DOACs for the treatment of CAT is available to date. In a meta-analysis from nine randomized controlled studies (n = 2310), in comparison with VKAs, LMWH showed a significant reduction in recurrent VTE events (RR, 0.52; 95% CI, 0.36-0.74), whereas DOACs did not (RR, 0.66; 95% CI, 0.39-1.11). Conversely, no difference in the risk of major bleeding was observed with LMWH (RR, 1.06; 95% CI, 0.5-2.23), whereas a non-significant reduction was observed with DOACs (RR, 0.78; 95% CI, 0.42-1.44) [37] . Another meta-analysis including an indirect network comparison between DOACs and LMWH, indicated comparable efficacy (RR, 1.08; 95% CI, 0.59-1.95, P = 0.81) and a nonsignificant relative risk towards improved safety with DOACs (RR = 0.67; 95% CI, 0.31-1.46; P = 0.31) [10] .
However, the relevance of comparisons between LMWH and DOACs based on available data is questionable because CAT patients included in these DOACs studies had a less severe/advanced disease, were less exposed to antineoplastic treatments and were at higher risk of recurrent VTE, as shown in control groups receiving VKAs ( Table 2 ). The benefit-risk ratio of DOACs in patients with cancer remains therefore questionable. Also, studies available to date with DOACs have substantial limitations as they lack stratification for cancer and consistency regarding the definition of active cancer, and they were not designed to make conclusions on this population at very high risk of VTE recurrence and bleeding. Furthermore, in most studies, patients with cancer eligible for long-term treatment with LMWH were not included and the choice of VKA as comparator is not fully relevant because they are suboptimal compared with LMWH in preventing VTE recurrence in this patient population.
These limitations should make clinicians refrain from using DOACs as first-line therapy for the treatment of CAT until head-to-head comparisons between these drugs and LMWH are available. Considering this paucity of data and the lack of cancer-specific treatment data, published guidelines do not recommend current use of DOACs in cancer patients [3] .
Several ongoing studies are assessing DOACs for cancer-associated thrombosis (clinicaltrials.gov: NCT 02744092; NCT02585713; NCT02583191; NCT01989845).
Among them, SELECT-d is a phase III, multicenter, open-label, randomized trial comparing rivaroxaban and dalteparin in a targeted sample size of 530 cancer patients with symptomatic venous thrombosis or incidental pulmonary embolism (Current Controlled Trials ISRCTN86712308). CASTA-DIVA is a pilot study comparing rivaroxaban and dalteparin in 200 patients with CAT (NCT02746185) (Fig. 1) . The HOKUSAI VTEcancer study is currently randomizing approximately 1000 patients with CAT to receive edoxaban and dalteparin. The study is expected to be completed by December 2017 (Current Controlled Trials NCT02073682) (Fig. 2) . CARAVAGGIO is another prospective randomized open blinded end-point (Probe) study on Apixaban for the treatment of venous thromboembolism in patients with cancer which is planned to start in March 2017 and to include also more than 1000 patients (Clinicaltrials.gov : NCT03045406).
Additional aspects regarding the choice of the anticoagulant regimen in patients with CAT

Influence of cancer progression and tumor type
The Canadian expert consensus recommendations state that anticoagulation should be continued beyond the initial 6 months of therapy in patients with advanced cancer who are in complete remission and for whom the short- CLOT [25] Dalteparin N = 672 CATCH [68] Tinzaparin N = 900 HOKUSAI [69] Edoxaban N = 208* EINSTEIN [69] Rivaroxaban N = 655* term risk of cancer recurrence is high, or in patients with active advanced cancer, or in the presence of other ongoing major risk factors for thrombosis [38] . In such situations, the continuation of LMWH and other therapeutic alternatives should be discussed. Risk stratification based on tumor type, stage of the disease and co-morbidities (hospitalization or immobilization, surgery, chemotherapy or radiotherapy, insertion of a CVC or localized tumor compression) is to be taken into account in the choice of the optimal anticoagulation therapy [38] . Cancer localizations, such as the ear, throat, nose, or upper respiratory or digestive systems, can make swallowing impossible and LMWH is the preferred option in these patients.
Renal failure
Unlike unfractionated heparin, LMWHs are mainly excreted by the kidney and they are therefore contra-indicated or should be used with caution in patients with creatinine clearance (CrCl) below 30 mL min À1 . However, the renal elimination of LMWHs is highly influenced by their molecular weight. There is consistent evidence that LMWHs with the highest molecular weight are less dependent on renal clearance [39] . Several pharmacokinetic studies have shown that anti-factor Xa activity with the short-term use of tinzaparin doesn't accumulate in patients with renal insufficiency with CrCl down to 20 mL min À1 [40] [41] [42] . The issue of managing cancer patients with renal insufficiency remains unaddressed by DOACs, partly eliminated by the renal route, as patients with a CrCl < 30 mL min À1 , highly prevalent in the cancer population, were excluded from these studies. Dabigatran is contraindicated in patients with a CrCl < 30 mL min À1 , whereas rivaroxaban and apixaban must be used with caution in patients with CrCl < 30 mL min
À1
and are not recommended in patients with CrCl < 15 mL min À1 . Even though they are usually considered in patients with severe renal impairment, VKAs should be used with caution in these patients because the accumulation of inactive metabolites leads to a labile international normalized ratio, with higher values leading to an increased risk of bleeding and rare although severe VKAinduced acute nephropathy [43] .
Drug-drug interactions
DOACs have fewer drug interactions than VKAs. However, DOACs' metabolism is influenced by either CYP 3A4 or P-gp pathways. Patients treated with dabigatran are exposed to few drug interactions, except with potent P-gp inhibitors [44, 45] . Rivaroxaban is partly metabolized by the liver through the CYP3A4 and CYP2J2 pathways and eliminated as inactive metabolites [46] [47] [48] . Potent inhibitors of CYP3A4 and P-gp may increase the plasma levels of rivaroxaban and are therefore contraindicated. The real clinical impact of potential DOAC drug interactions with chemotherapeutic and even noncytotoxic agents, which are substrates of these metabolic pathways, also (Table 3) remains unknown [22] , whereas LMWHs are compatible with most anticancer drugs. No data are available to date on the interaction of DOACs with these different anticancer drugs, such as tyrosine kinase inhibitors, dexamethasone or vinblastine. The metabolic impact on DOAC pharmacokinetics in the case of hepatic metastases is also not documented [49] .
Cancer patients are at risk of opportunistic or fungal infections; therefore, a checklist of potential interactions should be applied to avoid the use of strong inhibitors or inducers of P-gp and CYP3A4 [50] . The list is not exhaustive, with many supportive care agents such as neurokinin 1 receptor antagonists are used in emetogenic chemotherapies and influencing CYP3A4 activity [20] . Many of these possible interactions in cancer settings are theoretical, with no reported data so no clear practical stratification or adjustment could be proposed in the case of co-administration. Antidote and/or neutralization Neutralization is of major importance in cancer patients with a higher risk of hemorrhage. Few agents are available as antidotes to immediately reverse the action of DOACs, which may be a problem in the case of major bleeding or the need for urgent invasive procedures, especially in frail patients with cancer who are at higher risk of bleeding. Idarucizumab, a Fab antibody fragment, was shown to reverse the anticoagulant effects of dabigatran within minutes [51] . It is the only antidote available to date and specifically against dabigatran. Andexanet alfa, a recombinant modified human FXa protein, reduced anti-factor Xa activity in patients with acute major bleeding associated with FXa inhibitors [52] . Intravenous PER977 (Perosphere) was shown to restore hemostasis in subjects receiving 60 mg of edoxaban. Additional phase II clinical studies in subjects receiving edoxaban are ongoing [53] . Clinical data on the benefit of antidotes are still limited and the hemostatic control remains to be compared with conventional strategies such as prothrombin complex concentrates (PCC) in larger prospective studies. Substitutive strategies using PCC remain the recommended approach for reversing all the oral anticoagulants, with a reported variable efficacy [54] .
On the other hand, protamine sulfate is unable to completely reverse the anticoagulant effect of LMWH in the case of overdose and reversibility varies according to different LMWH species [55] . Thus, symptomatic treatment with both plasma and blood cell supplementation combined with PCC infusion is the only validated strategy in the case of major bleeding in cancer patients.
Issues with the parenteral use of LMWH
The burden of daily subcutaneous injections for a minimum of 6 months remains a major issue with LMWH. However, qualitative studies have shown that cancer patients' acceptance of daily injections is good and most prefer the convenience and 'empowerment' of LMWH [49] . There is a gap between patients' perceptions and their doctors' perceptions, as physicians tend to underestimate a patient's ability to accept long-term treatment with LMWH [56, 57] . A recent prospective observational study in 409 patients with CAT showed that long-term LMWH for a mean treatment duration of 5.3 AE 2.07 months was associated with very good convenience and a high degree of treatment satisfaction, based on scores from the Perception Anticoagulant Treatment Questionnaire [58, 59] .
Non-anticoagulant pleiotropic effects with potential benefit in cancer A growing body of evidence based on in vitro, in vivo and ex vivo studies suggests that LMWHs exert anticancer effects based on both anticoagulant and non-anticoagulant mechanisms [60] . LMWHs impair tumor angiogenesis, systemic inflammation, vascular compartment hyperreactivity, endothelial wall adhesion and metastatic invasion [61, 62] . However, the anticancer effects seen in in vitro and in vivo studies have been examined in observational and clinical studies and a survival benefit for LMWHs has not yet been observed. The potential impact of DOACs on other biological processes than FXa or FIIa-mediated actions in cancer remains to be demonstrated. As these LMWH properties are not known to be shared with DOACs, it is unclear whether they will have the same efficacy/safety in CAT patients as do heparin chains [20] . Numerous vascular disturbances involving various clotting factors that are exacerbated in the context of malignancy may be favorably altered by LMWH. Whether DOACs possess pleiotropic effects with anticancer extension properties is still unknown.
Conclusion
Having a simple, effective and affordable anticoagulant regimen for VTE treatment in cancer patients remains an unmet clinical need [49] (Table 4 ). Despite the limitation related to the need for daily subcutaneous injection, LMWH remains the first-line option for the treatment of acute VTE in patients with cancer. Whether DOACS may represent an alternative to LMWH for the long-term or extended treatment of cancer-associated VTE, in view of potential advantages, is currently or shortly being assessed in large clinical trials [36, 63] .
